232 related articles for article (PubMed ID: 22535331)
1. Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine.
Finger RP; Hoffmann AE; Fenwick EK; Wolf A; Kampik A; Kernt M; Neubauer AS; Hirneiss C
Br J Ophthalmol; 2012 Jul; 96(7):997-1002. PubMed ID: 22535331
[TBL] [Abstract][Full Text] [Related]
2. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration.
Finger RP; Guymer RH; Gillies MC; Keeffe JE
Ophthalmology; 2014 Jun; 121(6):1246-51. PubMed ID: 24518613
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
[TBL] [Abstract][Full Text] [Related]
4. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
Zweifel SA; Saroj N; Shapiro H; Freund KB
Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
[TBL] [Abstract][Full Text] [Related]
5. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
[TBL] [Abstract][Full Text] [Related]
6. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration.
van Asten F; Evers-Birkenkamp KU; van Lith-Verhoeven JJ; de Jong-Hesse Y; Hoppenreijs VP; Hommersom RF; Scholten AM; Hoyng CB; Klaver JH;
Acta Ophthalmol; 2015 Mar; 93(2):126-33. PubMed ID: 25488348
[TBL] [Abstract][Full Text] [Related]
7. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration.
Frennesson C; Nilsson UL; Peebo BB; Nilsson SE
Acta Ophthalmol; 2010 Jun; 88(4):420-5. PubMed ID: 19678811
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
[TBL] [Abstract][Full Text] [Related]
9. Rasch analysis reveals problems with multiplicative scoring in the macular disease quality of life questionnaire.
Finger RP; Fenwick E; Pesudovs K; Marella M; Lamoureux EL; Holz FG
Ophthalmology; 2012 Nov; 119(11):2351-7. PubMed ID: 22968142
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy.
Tabandeh H; Chaudhry NA; Boyer DS; Kon-Jara VA; Flynn HW
J Cataract Refract Surg; 2012 Apr; 38(4):677-82. PubMed ID: 22284725
[TBL] [Abstract][Full Text] [Related]
11. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
Park SS; Daftari I; Phillips T; Morse LS
Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
[TBL] [Abstract][Full Text] [Related]
12. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
14. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
[TBL] [Abstract][Full Text] [Related]
15. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
[TBL] [Abstract][Full Text] [Related]
16. Quality of life after macular translocation with 360 degrees peripheral retinectomy for age-related macular degeneration.
Cahill MT; Stinnett SS; Banks AD; Freedman SF; Toth CA
Ophthalmology; 2005 Jan; 112(1):144-51. PubMed ID: 15629835
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study.
Matamoros E; Maurel F; Léon N; Solomiac A; Bardoulat I; Joubert M; Hermans M; Moser E; Le Picard S; Souied EH; Leveziel N
Ophthalmologica; 2015; 234(3):151-9. PubMed ID: 26337381
[TBL] [Abstract][Full Text] [Related]
18. Change in vision-related quality of life and influencing factors in Asians receiving treatment for neovascular age-related macular degeneration.
Fenwick EK; Cheung GCM; Gan AT; Tan G; Lee SY; Wong D; Yeo I; Mathur R; Wong TY; Lamoureux EL
Br J Ophthalmol; 2018 Mar; 102(3):377-382. PubMed ID: 28659392
[TBL] [Abstract][Full Text] [Related]
19. The impact of vision impairment on vision-specific quality of life in Germany.
Finger RP; Fenwick E; Marella M; Dirani M; Holz FG; Chiang PP; Lamoureux EL
Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3613-9. PubMed ID: 21357395
[TBL] [Abstract][Full Text] [Related]
20. Vision-related quality of life in patients suffering from age-related macular degeneration.
Berdeaux GH; Nordmann JP; Colin E; Arnould B
Am J Ophthalmol; 2005 Feb; 139(2):271-9. PubMed ID: 15733988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
